A new autologous keratinocyte dressing treatment for non-healing diabetic neuropathic foot ulcers
Date
2004
Authors
Moustafa, M.
Simpson, C.
Glover, M.
Dawson, R.
Tesfaye, S.
Creagh, F.
Haddow, D.
Short, R.D.
Heller, S.
MacNeil, S.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Diabetic Medicine, 2004; 21(7):786-789
Statement of Responsibility
Conference Name
Abstract
Aims: To evaluate the use of a new cell-tailored carrier surface (TranCell) for delivery of autologous keratinocytes to promote wound healing in patients with chronic neuropathic foot ulcers.
Methods: TranCell is a sterile medical grade polymer coated with a plasma-polymerized functional surface containing 20% carboxylic acid which enables keratinocytes to attach and proliferate. Six diabetic patients with neuropathic ulcers resistant to conventional therapy were treated with weekly applications of autologous keratinocytes delivered on TranCell. A split-thickness skin biopsy was taken from each patient followed by isolation, expansion and freezing down of keratinocytes. Keratinocytes were thawed and seeded on TranCell 48 h prior to application. This procedure was repeated weekly in addition to conventional therapy until wound healing was achieved.
Results: Complete healing was achieved in six out of nine ulcers in six patients, a reduction in ulcer size was achieved in one ulcer and no response was seen in one ulcer. Treatment was discontinued in one patient due to development of Methicillin-Resistant Staphylococcus aureus (MRSA) after only three applications of TranCell. Wound healing took 6–17 applications over 6–20 weeks. There were no recurrences in the healed ulcers after a follow-up of 6 months.
Conclusions: TranCell delivery of autologous cells is a promising treatment for chronic diabetic foot ulcers with no side-effects and no recurrence in the healed ulcers.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright 2004 Diabetes UK